These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25785210)

  • 1. Hyperhemolysis Syndrome without Underlying Hematologic Disease.
    Eberly LA; Osman D; Collins NP
    Case Rep Hematol; 2015; 2015():180526. PubMed ID: 25785210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperhemolysis syndrome in anemia of chronic disease.
    Darabi K; Dzik S
    Transfusion; 2005 Dec; 45(12):1930-3. PubMed ID: 16371046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease.
    Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP
    Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab.
    Gupta S; Fenves A; Nance ST; Sykes DB; Dzik WS
    Transfusion; 2015 Mar; 55(3):623-8. PubMed ID: 25257194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Unusual Case of Delayed Hemolytic Transfusion Reaction With Hyperhemolysis Syndrome Due to Anti-Jk
    El Alaoui K; Benghiat FS; Colard M
    J Hematol; 2022 Apr; 11(2):66-70. PubMed ID: 35573755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition.
    Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A
    Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-N and anti-Do
    Unnikrishnan A; Pelletier JPR; Bari S; Zumberg M; Shahmohamadi A; Spiess BD; Michael MJ; Harris N; Harrell D; Mandernach MW
    Transfusion; 2019 Jun; 59(6):1907-1910. PubMed ID: 30768787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare antibody-associated hemolytic transfusion reaction and transfusion-related acute lung injury: a case report.
    Beck TN; Young NG; Erickson ML; Prats I
    BMC Surg; 2017 Apr; 17(1):48. PubMed ID: 28441942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
    Uhlmann EJ; Shenoy S; Goodnough LT
    Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions.
    Aygun B; Padmanabhan S; Paley C; Chandrasekaran V
    Transfusion; 2002 Jan; 42(1):37-43. PubMed ID: 11896310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperhemolysis syndrome in patients with sickle cell anemia: report of three cases.
    Santos B; Portugal R; Nogueira C; Loureiro M
    Transfusion; 2015 Jun; 55(6 Pt 2):1394-8. PubMed ID: 25677578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed hemolytic transfusion reaction due to anti-Jk(a).
    Vucelic D; Savic N; Djordjevic R
    Acta Chir Iugosl; 2005; 52(3):111-5. PubMed ID: 16813007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransfusion hyperhemolysis is arrested by targeting macrophage activation with novel use of Tocilizumab.
    Lee LE; Beeler BW; Graham BC; Cap AP; Win N; Chen F
    Transfusion; 2020 Jan; 60(1):30-35. PubMed ID: 31642065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment.
    Hannema SE; Brand A; van Meurs A; Smiers FJ
    Transfusion; 2010 Feb; 50(2):429-32. PubMed ID: 19788508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Hyperhemolysis Syndrome in a Patient with Known Sickle Cell Anemia Refractory to Steroids and IVIG Treated with Tocilizumab and Erythropoietin: A Case Report and Review of Literature.
    Menakuru SR; Priscu A; Dhillon V; Salih A
    Hematol Rep; 2022 Jul; 14(3):235-239. PubMed ID: 35893156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A suspected delayed hemolytic transfusion reaction mediated by anti-Joa.
    Jajosky RP; Lumm WC; Wise SC; Bollag RJ; Shikle JF
    Immunohematology; 2017 Jun; 33(2):73-75. PubMed ID: 28657766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A delayed hemolytic transfusion reaction (DHTR) with multiple alloantibodies (Anti-E, Jka, Dia, Fyb, and S) induced by E-antigen-negative, crossmatch-compatible blood.
    Yamane K; Yagihashi A; Sasaki M; Kuwashima K; Morio A; Watanabe N
    Immunopharmacol Immunotoxicol; 1998 Nov; 20(4):531-9. PubMed ID: 9805232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immuno-hematological findings in Delayed Hemolytic Transfusion Reaction (DHTR).
    Thonier V
    Transfus Clin Biol; 2019 May; 26(2):102-108. PubMed ID: 30885514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of hyperhemolysis syndrome in sickle cell disease and concomitant COVID-19.
    Green A; Jones H; Nero A; Ibrahim IF; Sarode R; Scheid LM; Webb CB; Adkins BD; Yates SG
    Transfus Apher Sci; 2023 Aug; 62(4):103712. PubMed ID: 37149492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report and review: alloimmunization, delayed hemolytic transfusion reaction, and clinically significant anti-Yt(a) in a patient with Beta-thalassemia/sickle cell anemia.
    Hillyer CD; Hall JM; Tiegerman KO; Berkman EM
    Immunohematology; 1991; 7(4):102-6. PubMed ID: 15946040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.